983 related articles for article (PubMed ID: 15837967)
1. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
2. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
3. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K;
J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
8. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-21-S12-26. PubMed ID: 9331115
[TBL] [Abstract][Full Text] [Related]
9. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
[TBL] [Abstract][Full Text] [Related]
14. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Jeremić B; Milicić B; Acimović L; Milisavljević S
J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
20. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]